Stock Track | Akeso Plummets 5.07% Intraday on Disappointing Ivonescimab Phase III Interim Results

Stock Track

May 18

Akeso's stock plummeted 5.07% during intraday trading, extending recent declines for the biopharmaceutical company.

The sharp drop follows market digestion of disappointing interim results from the global pivotal Phase III HARMONi-3 study of its drug ivonescimab. The data showed that the squamous cell carcinoma cohort for the first-line treatment of metastatic non-small cell lung cancer failed to meet the pre-specified statistical significance threshold, raising significant concerns among investors about whether the strong clinical results observed in the Chinese patient population can be replicated globally.

The news has led to a sustained sell-off, with the stock having retreated over 26% from its April high, and contributed to broader pressure on the biotech sector during the session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1125138786"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1125138786\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1125138786?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-18 10:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125138786","market":"sg","top_or_hot":-1,"title":"Stock Track | Akeso Plummets 5.07% Intraday on Disappointing Ivonescimab Phase III Interim Results","media":"Stock Track","content":"<p>Akeso's stock plummeted 5.07% during intraday trading, extending recent declines for the biopharmaceutical company.</p><p>The sharp drop follows market digestion of disappointing interim results from the global pivotal Phase III HARMONi-3 study of its drug ivonescimab. The data showed that the squamous cell carcinoma cohort for the first-line treatment of metastatic non-small cell lung cancer failed to meet the pre-specified statistical significance threshold, raising significant concerns among investors about whether the strong clinical results observed in the Chinese patient population can be replicated globally.</p><p>The news has led to a sustained sell-off, with the stock having retreated over 26% from its April high, and contributed to broader pressure on the biotech sector during the session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Akeso Plummets 5.07% Intraday on Disappointing Ivonescimab Phase III Interim Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Akeso Plummets 5.07% Intraday on Disappointing Ivonescimab Phase III Interim Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-18 10:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Akeso's stock plummeted 5.07% during intraday trading, extending recent declines for the biopharmaceutical company.</p><p>The sharp drop follows market digestion of disappointing interim results from the global pivotal Phase III HARMONi-3 study of its drug ivonescimab. The data showed that the squamous cell carcinoma cohort for the first-line treatment of metastatic non-small cell lung cancer failed to meet the pre-specified statistical significance threshold, raising significant concerns among investors about whether the strong clinical results observed in the Chinese patient population can be replicated globally.</p><p>The news has led to a sustained sell-off, with the stock having retreated over 26% from its April high, and contributed to broader pressure on the biotech sector during the session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1125138786","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125138786","pubTimestamp":1779073043,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Akeso's stock plummeted 5.07% during intraday trading, extending recent declines for the biopharmaceutical company.The sharp drop follows market digestion of disappointing interim results from the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"个股追踪|康方生物盘中暴跌5.07%因ivonescimab III期中期业绩令人失望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"Akeso's stock plummeted 5.07% during intraday trading, extending recent declines for the biopharmaceutical company.The sharp drop follows market digestion of disappointing interim results from the global pivotal Phase III HARMONi-3 study of its drug ivonescimab. The data showed that the squamous cell carcinoma cohort for the first-line treatment of metastatic non-small cell lung cancer failed to meet the pre-specified statistical significance threshold, raising significant concerns among investors about whether the strong clinical results observed in the Chinese patient population can be replicated globally.The news has led to a sustained sell-off, with the stock having retreated over 26% from its April high, and contributed to broader pressure on the biotech sector during the session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}